Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Couriel

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationRaymond Wong, Munir Shahjahan, Xuemei Wang, et al.
Haematologica|June 29, 2014
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myelomaDominik Dytfeld, Jagoda Jasielec, Kent A Griffith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.
The New England Journal of Medicine|August 9, 2013
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathMark T Vander Lugt, Thomas M Braun, Samir Hanash, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group ReportKirk R Schultz, David B Miklos, Daniel Fowler, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar, Borje S Andersson, Daniel Couriel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2005
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group reportAlexandra H Filipovich, Daniel Weisdorf, Steven Pavletic, et al.
Haematologica|August 5, 2018
Upper gastrointestinal acute graft-<i>versus</i>-host disease adds minimal prognostic value in isolation or with other graft-<i>versus</i>-host disease symptoms as currently diagnosed and treatedSarah Nikiforow, Tao Wang, Michael Hemmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2020
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyAyman Saad, Marcos de Lima, Sarah Anand, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationRaymond Wong, Munir Shahjahan, Xuemei Wang, et al.
Haematologica|June 29, 2014
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myelomaDominik Dytfeld, Jagoda Jasielec, Kent A Griffith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.
The New England Journal of Medicine|August 9, 2013
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathMark T Vander Lugt, Thomas M Braun, Samir Hanash, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group ReportKirk R Schultz, David B Miklos, Daniel Fowler, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar, Borje S Andersson, Daniel Couriel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2005
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group reportAlexandra H Filipovich, Daniel Weisdorf, Steven Pavletic, et al.
Haematologica|August 5, 2018
Upper gastrointestinal acute graft-<i>versus</i>-host disease adds minimal prognostic value in isolation or with other graft-<i>versus</i>-host disease symptoms as currently diagnosed and treatedSarah Nikiforow, Tao Wang, Michael Hemmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2020
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyAyman Saad, Marcos de Lima, Sarah Anand, et al.
Pageof 8